Navigation Links
Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
Date:10/22/2008

COLUMBUS, Ohio, Oct. 22 /PRNewswire/ -- Last week, Roxane Laboratories, Inc. launched its calcium acetate capsules, 667mg. Since the October 15 exclusive launch of this product, Roxane Laboratories, Inc., has experienced tremendous demand.

Roxane Laboratories' calcium acetate capsules, 667mg are the only AB rated generic alternative to PhosLo(R) (calcium acetate) capsules, used in the treatment of high levels of phosphate in patients with chronic renal failure. Annual sales of PhosLo(R) (calcium acetate) capsules are approximately $84.8 million(1).

Full prescribing information for calcium acetate capsules, 667mg is available on the Roxane Laboratories website at http://www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information hotline at 1-800-962-8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.

(1) IMS MAT dollar sales ending 6/2008

PhosLo(R) is a registered trademark of Fresenius Medical Care.


'/>"/>
SOURCE Roxane Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
2. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
3. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
4. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
5. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
6. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
7. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
8. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
9. IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
10. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016   CytoSorbents Corporation (NASDAQ: CTSO ... Union approved CytoSorb ® cytokine adsorber to treat ... announced that Dr. Phillip Chan , Chief Executive ... Micro Main Event investor conference held from December ... Sunset Boulevard Hotel in Los Angeles, California ...
(Date:12/2/2016)... 2016 On Thursday, the NASDAQ Composite ... Jones Industrial Average edged 0.36% higher, to finish at 19,191.93; ... were broad based as six out of nine sectors ended ... on the following Services equities: Myriad Genetics Inc. (NASDAQ: ... INC Research Holdings Inc. (NASDAQ: INCR ), and ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report ... parents report speaking with their child about sex related topics, less than 60 percent ... is proud to announce the launch of its second edition of the “Sexual Wellness” ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Sourced from the ... some unique properties including its unmatched natural purity of just 6 ppm TDS (Total ... crisp. , Nothing Water has been available in several ShopRite and FoodTown stores in ...
(Date:12/2/2016)... ... December 02, 2016 , ... On ... individuals and families from eight different sites throughout Miami-Dade and Broward counties. This ... volunteers worked very hard on Thanksgiving morning by putting together individual meals via ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge ... comprehensive in-house dental plan for all patients. Understanding that budget can play a ... patients a number of perks, including discounts on many valuable dental treatments. Options ...
(Date:11/30/2016)... ... November 30, 2016 , ... In recent policy ... focus of public policymakers and system stakeholders in many states. To help them ... Medical Price Index for Workers’ Compensation, Eighth Edition (MPI-WC) . , “If you ...
Breaking Medicine News(10 mins):